Your browser doesn't support javascript.
loading
Gefitinib versus Erlotinib as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer / 南方医科大学学报
Journal of Southern Medical University ; (12): 446-449, 2015.
Artigo em Chinês | WPRIM | ID: wpr-239159
ABSTRACT
<p><b>OBJECTIVE</b>To compare the efficacy of the erlotinib versus gefitinib in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC.</p><p><b>METHODS</b>Fifty patients with untreated advanced EGFR mutation- positive NSCLC were randomly divided into gefitinib group (n=27) and erlotinib group (n=23). The progression-free survival, objective response rate and disease control rate were evaluated to compare the efficacy of gefitinib and erlotinib.</p><p><b>RESULTS</b>There were no significant differences in the objective response rate (P=0.711) and disease control rate (P=0.861) between the two groups. The progression-free survival of gefitinib group and erlotinib group was 8.0 months and 10.0 months, respectively. The efficacy of the two drugs was similar (P=0.293).</p><p><b>CONCLUSION</b>There is no significant differences between gefitinib and erlotinib in the first-line treatment of patients with advanced EGFR mutation-positive NSCLC.</p>
Assuntos
Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Quinazolinas / Carcinoma Pulmonar de Células não Pequenas / Intervalo Livre de Doença / Usos Terapêuticos / Tratamento Farmacológico / Receptores ErbB / Cloridrato de Erlotinib / Neoplasias Pulmonares / Metabolismo / Mutação Limite: Humanos Idioma: Chinês Revista: Journal of Southern Medical University Ano de publicação: 2015 Tipo de documento: Artigo

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: WPRIM (Pacífico Ocidental) Assunto principal: Quinazolinas / Carcinoma Pulmonar de Células não Pequenas / Intervalo Livre de Doença / Usos Terapêuticos / Tratamento Farmacológico / Receptores ErbB / Cloridrato de Erlotinib / Neoplasias Pulmonares / Metabolismo / Mutação Limite: Humanos Idioma: Chinês Revista: Journal of Southern Medical University Ano de publicação: 2015 Tipo de documento: Artigo